Cyclerion Therapeutics (CYCN) Institutional Ownership $3.28 +0.03 (+0.89%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclerion Therapeutics (NASDAQ:CYCN)CurrentInstitutional OwnershipPercentage75.62%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$34.17KNumber ofInstitutional Sellers(last 12 months)0 Get CYCN Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclerion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYCN Institutional Buying and Selling by Quarter Cyclerion Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/13/2025 Renaissance Technologies LLC10,611$34K0.0%N/A0.392% 2/14/2024 Tyndall Capital Partners L P164,429$551K100.0%+11.3%6.711% 11/14/2023 Tyndall Capital Partners L P147,712$505K100.0%N/A6.129% 8/11/2023 Artal Group S.A.138,955$572K0.0%-95.0%5.766% 5/9/2022Trustcore Financial Services LLC292,645$325K0.0%+47.7%0.674% 2/14/2022 Diametric Capital LP100,480$173K0.1%+43.9%0.232% 2/10/2022 Acadian Asset Management LLC249,792$428K0.0%N/A0.577% 11/16/2021 Two Sigma Advisers LP647,700$1.99M0.0%+98.4%1.495% 11/16/2021 Two Sigma Investments LP390,596$1.20M0.0%+154.1%0.902% 11/15/2021 Pura Vida Investments LLC422,311$1.30M0.0%-16.8%0.975% Get the Latest News and Ratings for CYCN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2021 Eversept Partners LP371,955$1.14M0.1%N/A0.859% 11/15/2021 Franklin Resources Inc.116,035$356K0.0%N/A0.268% 11/12/2021 Jump Financial LLC52,000$160K0.0%N/A0.120% 11/12/2021 Geode Capital Management LLC490,660$1.51M0.0%+27.5%1.134% 9/17/2021 Virtu Financial LLC80,384$313K0.0%-9.2%0.186% 9/3/2021Parametric Portfolio Associates LLC12,596$49K0.0%-52.0%0.029% 8/25/2021 Marshall Wace LLP28,863$113K0.0%N/A0.067% 8/18/2021 Ikarian Capital LLC509,924$1.99M0.2%+70.0%1.178% 8/17/2021 Millennium Management LLC389,041$1.52M0.0%N/A0.899% 8/17/2021 Boothbay Fund Management LLC66,977$261K0.0%+96.3%0.155% 8/16/2021 Cubist Systematic Strategies LLC17,084$67K0.0%N/A0.039% 8/16/2021 Diametric Capital LP80,336$313K0.2%N/A0.186% 8/16/2021 Slate Path Capital LP7,157,601$27.92M1.6%+15.5%16.539% 8/16/2021 Charles Schwab Investment Management Inc.129,628$506K0.0%-35.1%0.300% 8/16/2021 State Street Corp83,321$325K0.0%-79.2%0.193% 8/16/2021Tibra Equities Europe Ltd85,000$332K0.1%N/A0.196% 8/16/2021 Goldman Sachs Group Inc.36,317$141K0.0%-9.4%0.084% 8/16/2021 Marshall Wace LLP28,863$113K0.0%N/A0.067% 8/13/2021 Renaissance Technologies LLC284,744$1.11M0.0%+22.1%0.658% 8/13/2021 Northern Trust Corp64,616$252K0.0%-73.0%0.149% 8/13/2021 Geode Capital Management LLC384,820$1.50M0.0%-21.0%0.889% 8/13/2021 Vanguard Group Inc.1,423,532$5.55M0.0%-14.7%3.289% 8/13/2021 FMR LLC2,674,811$10.43M0.0%-1.9%6.181% 8/12/2021 Prime Capital Investment Advisors LLC22,250$87K0.0%N/A0.051% 8/12/2021 XTX Topco Ltd17,968$70K0.0%+34.4%0.042% 8/12/2021 Dimensional Fund Advisors LP158,994$620K0.0%+160.1%0.367% 8/12/2021 JPMorgan Chase & Co.59,786$233K0.0%-43.7%0.138% 8/12/2021Ergoteles LLC96,100$375K0.0%N/A0.222% 8/11/2021 Bank of New York Mellon Corp66,792$260K0.0%-31.9%0.154% 8/11/2021 Deutsche Bank AG65,900$257K0.0%-18.7%0.152% How Trade Wars Are Creating Fresh Opportunities for Investors (Ad)Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”Position yourself ahead of the next move—get the full report here.8/11/2021 Susquehanna Fundamental Investments LLC105,572$412K0.0%N/A0.244% 5/19/2021 Virtu Financial LLC88,551$247K0.0%N/A0.259% 5/18/2021 D. E. Shaw & Co. Inc.68,472$191K0.0%-62.2%0.201% 5/17/2021 PDT Partners LLC42,900$120K0.0%+74.4%0.126% 5/17/2021 Walleye Trading LLC10,000$28K0.0%N/A0.029% 5/17/2021 Walleye Capital LLC15,000$42K0.0%N/A0.044% 5/17/2021 Ikarian Capital LLC300,000$836K0.0%N/A0.879% 5/14/2021 XTX Topco Ltd13,365$37K0.0%N/A0.039% 5/13/2021QS Investors LLC116,035$324K0.0%+13.1%0.340% 5/13/2021 Barclays PLC18,516$52K0.0%+159.0%0.054% 5/13/2021 Renaissance Technologies LLC233,200$651K0.0%+1,202.8%0.683% 5/12/2021 Northern Trust Corp239,015$667K0.0%-7.0%0.700% 5/12/2021 Geode Capital Management LLC486,959$1.36M0.0%+12.2%1.427% 5/12/2021 JPMorgan Chase & Co.106,102$296K0.0%+19.1%0.311% 5/11/2021 New York State Common Retirement Fund12,070$34K0.0%-91.0%0.035% 5/10/2021 Russell Investments Group Ltd.124,075$345K0.0%+400.2%0.363% 5/10/2021 Bank Julius Baer & Co. Ltd Zurich12,000$33K0.0%-33.2%0.035% 5/7/2021BlackRock Inc.1,685,485$4.70M0.0%+5.1%4.938% 3/8/2021 Dimensional Fund Advisors LP63,735$195K0.0%+8.7%0.187% (Data available from 1/1/2016 forward) CYCN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYCN shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclerion Therapeutics shares: Artal Group S.A. ($572K), and Tyndall Capital Partners L P ($551K), Renaissance Technologies LLC ($34K).Learn more on CYCN's institutional investors. What percentage of Cyclerion Therapeutics stock is owned by institutional investors? 75.62% of Cyclerion Therapeutics stock is owned by institutional investors. Learn more on CYCN's institutional investor holdings. Which institutional investors have been buying Cyclerion Therapeutics stock? The following institutional investors have purchased Cyclerion Therapeutics stock in the last 24 months: Tyndall Capital Partners L P ($164.43K), and Renaissance Technologies LLC ($10.61K). How much institutional buying is happening at Cyclerion Therapeutics? Institutional investors have bought a total of 175,040 shares in the last 24 months. This purchase volume represents approximately $595.34K in transactions. Which Cyclerion Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Cyclerion Therapeutics stock in the last 24 months: Artal Group S.A. ($2.64M). How much institutional selling is happening at Cyclerion Therapeutics? Institutional investors have sold a total of 2,640,167 shares in the last 24 months. This volume of shares sold represents approximately $10.85M in transactions. Related Companies FBRX Institutional Ownership PLUR Institutional Ownership ATHE Institutional Ownership RNXT Institutional Ownership ATRA Institutional Ownership PRLD Institutional Ownership XLO Institutional Ownership SCYX Institutional Ownership ACRV Institutional Ownership BRNS Institutional Ownership This page (NASDAQ:CYCN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.